Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Peking University WBL Biotech is a Chinese pharmaceutical company specializing in the development and manufacturing of modern Chinese medicine and biological products. The company is best known for its flagship product, Xuezhikang, a proprietary red yeast rice extract used for the treatment of hyperlipidemia and the prevention of cardiovascular diseases. Originally established as a high-tech enterprise under Peking University, the company has integrated traditional Chinese medicine with modern pharmacological standards. In 2013, Luye Pharma Group acquired a controlling interest in the company, integrating its cardiovascular portfolio into Luye's broader commercial infrastructure.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Peking University WBL Biotech.